The entire series of Euthyrox N 25 µg tablets has been removed from the market following a quality discrepancy that exceeded active‑ingredient limits; patients advised to stop use.
Recall Announcement
On November 7, a notification of withdrawal was issued, removing the product from circulation.
Product Details
The recall covers 100‑tablet packs of Euthyrox N 25 µg, drawn from batch G02PXT, each with an expiry date of 29 February 2028.
Reason for Recall
The decision followed the discovery of a quality inconsistency: the active‑ingredient content exceeded the regulatory limit.
What Patients Should Do
According to the Chief Pharmaceutical Inspector, the law prohibits trading or using medicinal products that fail to meet quality standards and requires their destruction; therefore, patients who have obtained these tablets should not take them.